NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT AND INVESTORS SHOULD NOT ACQUIRE ANY ORDINARY SHARES IN INDIVIOR PLC EXCEPT ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS PUBLISHED BY INDIVIOR PLC ON 17 NOVEMBER 2014 AND ANY SUPPLEMENT OR AMENDMENT THERETO
SLOUGH, United Kingdom, Dec. 23, 2014 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior") will begin trading on the London Stock Exchange's main market at 8 a.m. GMT today following the admission of 718,577,616 of its ordinary shares to the premium listing segment of the Official List of the UK Listing Authority. Indivior will trade under the ticker "INDV". Indivior is a global specialty pharmaceutical company committed to expanding treatment access and pioneering innovative therapies for the chronic diseases of addiction and related mental health disorders.
"This is an exciting time for Indivior, our shareholders and the patients we serve worldwide. We made great strides with Reckitt Benckiser Group's support as Reckitt Benckiser Pharmaceuticals, and we now have the opportunity to continue our efforts to transform the global addiction treatment landscape under our own, focused direction and management. With the recent selection of the Executive Committee and Board of Directors, our experience in expanding treatment accessibility and our growing pipeline, we are confident in Indivior's future," said Shaun Thaxter, Chief Executive Officer of Indivior. "We are building upon our understanding of the patient journey to continue bringing to market novel solutions that advance treatment in opioid dependence and combat broader addiction epidemics and other mental health disorders."
In July 2014, the Reckitt Benckiser Group (the "RB Group") announced it was pursuing a demerger of the Reckitt Benckiser Pharmaceuticals business with a separate UK listing. At the RB Group General Meeting on December 11, 2014, shareholders voted in favour of the demerger. In the demerger, RB Group shareholders have received one ordinary share in Indivior for each ordinary share in RB Group that they hold. RB Group's ordinary shares will continue trading under the symbol RB-LN.
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio featuring SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet and SUBUTEX® (buprenorphine) Sublingual Tablet, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction – including opiate overdose, alcohol use disorders and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Headquartered in the United States in Richmond, Va., Indivior employs more than 700 individuals globally and its portfolio is available in over 40 countries worldwide. Visit www.Indivior.com to learn more.
This document does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in any jurisdiction.
The ordinary shares of Indivior have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the US and may not be offered or sold within the US, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the US. There has been no public offering of the ordinary shares of Indivior in the US for the purposes of the Securities Act.
This announcement may contain forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. Although we believe our expectations, beliefs and assumptions are reasonable, reliance should not be placed on any such statements because, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and our plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Neither Indivior nor any other person undertakes any obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, further events or otherwise. Past performance is not an indicator of future performance.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/indivior-plc-admission-to-the-official-list-and-to-trading-on-the-london-stock-exchange-300013305.html
SOURCE Indivior PLC
For further information: Media, Justine McIlroy | Anna Carruth, Brunswick Group, +44207 404 5959, Beth Keshishian, Biosector 2, +1 212-229-8417, [email protected], or Investor, Tom Corran, Indivior, Director, Investor Relations, +44(0)175 321 7800, http://www.Indivior.com